Current methodological issues in the economic assessment of personalized medicine

Value in Health

Volumn 16, Issue 6 SUPPL., 2013, Pages

  Annemans, Lieven ^a   Redekop, Ken ^b   Payne, Katherine ^c  

^a GHENT UNIVERSITY   (Belgium)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

guidelines; health economics; modeling; personalized medicine

Indexed keywords

TRASTUZUMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE MANAGEMENT; ECONOMIC EVALUATION; HEALTH CARE; INFORMATION PROCESSING; LABORATORY DIAGNOSIS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION;

GUIDELINES; HEALTH ECONOMICS; MODELING; PERSONALIZED MEDICINE;

BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, ECONOMIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84884190040     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.06.008     Document Type: Article

References (27)

1. N. Crabb, M. Marlow, H. Bell, and A. Newland The NICE Diagnostics Assessment Programme Health Pol Technol 1 2012 5 7
2. M.F. Drummond, and T.O. Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313 1996 275 283
3. N. Fleeman, C. McLeod, and A. Bagust The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation Health Technol Assess 14 2010 1 157 iii
4. N. Fleeman, C. Martin Saborido, and K. Payne The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review Health Technol Assess 15 2011 1 102
5. L. Moja, L. Tagliabue, and S. Balduzzi Trastuzumab containing regimens for early breast cancer Cochrane Database Syst Rev 2012 4 CD006243
6. Centers for Disease Control and Prevention, Office of Public Health Genomics. Genomic Testing: ACCE Model Process for Evaluating Genetic Tests. Druid Hills, GA: Centers for Disease Control and Prevention, 2010.
7. Alzheimer's Association. Genetic testing. Available from: http://www.alz.org/national/documents/topicsheet-genetictesting.pdf. [Accessed April 1, 2013].
8. D.G. Fryback, and J.R. Thornbury The efficacy of diagnostic imaging Med Decis Making 11 1991 88 94
9. Payne K, Thompson AJ. Economics of pharmacogenomics: rethinking beyond QALYs? Curr Pharmacogenomics Person Med 2013. In press
10. P.J. Valk, R.G. Verhaak, and M.A. Beijen Prognostically useful gene-expression profiles in acute myeloid leukemia N Engl J Med 350 2004 1617 1628
11. M. Westwood, M. Al, and L. Burgers A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD Health Technol Assess 17 2013 1 243
12. J. Bilcke, P. Beutels, M. Brisson, and M. Jit Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide Med Decis Making 31 2011 675 692
13. M.D. Rawlins, and A.J. Culyer National Institute for Clinical Excellence and its value judgments BMJ 329 2004 224 227
14. K. Payne, and F.H. Shabaruddin Cost-effectiveness analysis in pharmacogenomics Special 10th year anniversary edition of Pharmacogenomics 11 2010 643 646
15. M.O. Soares, L. Bojke, and J. Dumville Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration Stat Med 30 2011 2363 2380
16. K.A. Phillips, and S.L. Van Bebber A systematic review of cost-effectiveness analyses of pharmacogenomic interventions Pharmacogenomics 5 2004 1139 1149
17. S. Vegter, C. Boersma, and M. Rozenbaum Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines Pharmacoeconomics 26 2008 569 587
18. W.B. Wong, J.J. Carlson, R. Thariani, and D.L. Veenstra Cost effectiveness of pharmacogenomics: a critical and systematic review Pharmacoeconomics 28 2010 1001 1013
19. L. Annemans, B. Geneste, and B. Jolain Early modelling for assessing health and economic outcomes of drug therapy Value Health 3 2000 427 434
20. K. Payne, M. McAllister, and L.M. Davies Valuing the economic benefits of complex interventions: when maximising health is not sufficient Health Econ 22 2013 258 271
21. M. Drummond, D. Brixner, and M. Gold Toward a consensus on the QALY Value Health 12 Suppl. 2009 s31 s35
22. E. Stolk, and J.J. Busschbach Validity and feasibility of the use of condition-specific outcome measures in economic evaluations Qual Life Res 12 4 2006 363 371
23. J. Coast, T.N. Flynn, and L. Natarajan Valuing the ICECAP capability index for older people Soc Sci Med 67 2008 874 882
24. A.L. Nelson, J.T. Cohen, D. Greenberg, and D.M. Kent Much cheaper, almost as good: decrementally cost-effective medical innovation Ann Intern Med 151 2009 662 667
25. D.M. Kent, A.M. Fendrick, and K.M. Langa New and dis-improved: on the evaluation and use of less effective, less expensive medical interventions Med Decis Making 24 2004 281 286
26. D. Liew, K. Webb, S. Marbaix, and L. Annemans Changes to the statin prescribing policy in Belgium: potential impact in clinical and economic terms Am J Cardiovasc Drugs 12 2012 225 232
27. O'Connor D, Green S, Higgins J. Defining the review question and developing criteria for including studies. In: Higgins J, Green S, eds., Cochrane Handbook of Systematic Reviews of Intervention Version 510 (updated March 2011). Oxford, UK: The Cochrane Collaboration, 2011.